Telomir Pharmaceuticals (TELO) Long-Term Debt Issuances (2023 - 2024)
Telomir Pharmaceuticals (TELO) posted Long-Term Debt Issuances of -$867891.0 for Q4 2024, down 914.73% sequentially from -$85529.0 in Q3 2024, and down 191.18% YoY from $951881.0 in Q1 2024.
Telomir Pharmaceuticals (TELO) Long-Term Debt Issuances (2023 - 2024) Analysis & Trends
Telomir Pharmaceuticals has reported Long-Term Debt Issuances for 2 years, with the latest figure at -$867891.0 in Q4 2024.
- Quarterly Long-Term Debt Issuances fell 191.18% year-over-year to -$867891.0 in Q4 2024, while the trailing twelve-month figure through Dec 2024 was -$433945.0 (down 126.09% YoY) and the FY2024 annual result came in at -$433945.0, down 126.09% from the prior year.
- Long-Term Debt Issuances slipped to -$867891.0 in Q4 2024 per TELO's latest filing, from -$85529.0 in the prior quarter.
- Over five years, Long-Term Debt Issuances peaked at $951881.0 in Q4 2023 and troughed at -$867891.0 in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Debt Issuances (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Telomir Pharmaceuticals | 69.05 Mn | 69.05 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | -867,891.00 |
| Dec 31, 2024 | -867,891.00 |
| Sep 30, 2024 | -85,529.00 |
| Sep 30, 2024 | -85,529.00 |
| Mar 31, 2024 | 519,475.00 |
| Mar 31, 2024 | 519,475.00 |
| Dec 31, 2023 | 951,881.00 |
| Dec 31, 2023 | 951,881.00 |
| Sep 30, 2023 | 130,021.00 |
| Sep 30, 2023 | 130,021.00 |
| Jun 30, 2023 | 317,389.00 |
| Jun 30, 2023 | 317,389.00 |
| Mar 31, 2023 | 263,873.00 |
| Mar 31, 2023 | 263,873.00 |